Il carcinoma della prostata nell'anziano: Quale terapia?

Translated title of the contribution: Prostate cancer in the elderly: Which therapy?

Giuseppe Procopio, V. Guadalupi, M. O. Giganti, S. Stagni, M. Alù, R. Valdagni, E. Bajetta

Research output: Contribution to journalArticlepeer-review


Prostate cancer is the most common cancer in the world Western countries and represents the second cause of death for oncological disease in men. While hormone-based therapy is usually effective initially, the majority of prostate cancer will develop hormonoresistance and often metastases, after which treatment options are limited. A chemotherapy including docetaxel has been shown to improve the overall survival and clinical benefit in these clinical conditions; however, as a chemotherapy regimen some adverse events are associated, there is controversy about the right time to initiate and the best duration's treatment. Additionally, age and comorbidities sometimes precludes the use of some antitumoral agents. According to this, new treatment options are needed for patients affected by castration resistant prostate cancer (CRPC) in order to improve the disease control without a detrimental effect in their quality of life.

Translated title of the contributionProstate cancer in the elderly: Which therapy?
Original languageItalian
Pages (from-to)52-57
Number of pages6
JournalGeriatric and Medical Intelligence
Issue number1
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Prostate cancer in the elderly: Which therapy?'. Together they form a unique fingerprint.

Cite this